Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.

Journal of the American Society of Cytopathology - 1 Jan 2000

Guo Ming, Shlyakhova Natalya, Khanna Abha, Tinnirello Agata A, Schmeler Kathleen M, Hwang Jessica, Sturgis Erich M, Stewart John

Abstract excerpt

INTRODUCTION: The cobas (Roche Diagnostics, Indianapolis, IN) HPV assay was approved by the US Food and Drug Administration for human papillomavirus (HPV) testing in SurePath (Becton Dickinson, Franklin Lakes, NJ) Papanicolaou specimens for cervical cancer prevention. To validate the cobas HPV assay in SurePath specimens in our institution, we compared its accuracy and clinical efficacy to that of the Cervista...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alphapapillomavirus
Share to Cervix Uteri

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Data Accuracy

Share to Early Detection of Cancer

Share to Mass Screening

Share to Papanicolaou Test

Share to Uterine Cervical Dysplasia

Share to Vaginal Smears

Source

Identifiers

PMID: 33967024
DOI: 10.1016/j.jasc.2021.04.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.PMID 33967024Read ↗

Analytical performance of cervista HPV 16/18 in SurePath pap specimens.Semantic proximity Read ↗

A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes.Semantic proximity Read ↗

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.Semantic proximity Read ↗

Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening.Semantic proximity Read ↗

High-Risk Human Papillomavirus Detection via Cobas® 4800 and REBA HPV-ID® Assays.Semantic proximity Read ↗

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the International Guidelines for Human Papillomavirus Test Requirements for Cervical ScreeningSemantic proximity Read ↗

Comparison of a Newly Developed HPV Genotyping Assay (Mojin HPV Kit) with Cobas 4800 HPV Test for Detection of High-Risk HPV in Specimens Collected in SurePath Solution.Semantic proximity Read ↗

Cobas HPV test for first-line screening for cervical cancerSemantic proximity Read ↗

Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.Semantic proximity Read ↗

[Evaluation of cobas 4800 high-risk HPV test as a tool in cervical cancer screening and cytology triage].Semantic proximity Read ↗

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.Semantic proximity Read ↗

Comparative evaluation of AMPLICOR HPV PCR and Linear Array assays on SurePath liquid-based Pap samples for the detection of high-risk HPV genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.